Osteoarthritis, part of life or a curable disease? A bird's‐eye view
M Englund - Journal of Internal Medicine, 2023 - Wiley Online Library
Osteoarthritis (OA) is a chronic joint disease caused by disruption of joint homeostasis by a
variety of systemic and biomechanical factors. The disease is characterized by degradation …
variety of systemic and biomechanical factors. The disease is characterized by degradation …
[HTML][HTML] A review of current approaches to pain management in knee osteoarthritis with a focus on Italian clinical landscape
S Giaretta, A Magni, A Migliore, S Natoli… - Journal of Clinical …, 2024 - mdpi.com
The global cases of knee osteoarthritis (KOA) are projected to increase by 74.9% by 2050.
Currently, over half of patients remain dissatisfied with their pain relief. This review …
Currently, over half of patients remain dissatisfied with their pain relief. This review …
Innovation in targeted intra-articular therapies for osteoarthritis
R Assi, J Quintiens, S Monteagudo, RJ Lories - Drugs, 2023 - Springer
Osteoarthritis is the most common chronic joint disease characterized by progressive
damage to the joints, leading to pain and loss of function. There is currently no cure or …
damage to the joints, leading to pain and loss of function. There is currently no cure or …
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion
L Pan, L Nagib, S Ganguly, A Moorthy… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Osteoarthritis (OA) is a chronic, degenerative, and debilitating disease
associated with significant long-term morbidity and disability. The pathogenesis of OA is not …
associated with significant long-term morbidity and disability. The pathogenesis of OA is not …
What is new in pharmacological treatment for osteoarthritis?
Osteoarthritis (OA) is a degenerative joint disease in which structural changes of hyaline
articular cartilage, subchondral bone, ligaments, capsule, synovium, muscles, and …
articular cartilage, subchondral bone, ligaments, capsule, synovium, muscles, and …
Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials
J Tambiah, S Kennedy, C Swearingen… - …, 2024 - academic.oup.com
Objective Developing knee osteoarthritis (OA) treatments is challenging due to assessing
pain and joint structure outcomes within a highly heterogeneous disease. Lorecivivint (LOR) …
pain and joint structure outcomes within a highly heterogeneous disease. Lorecivivint (LOR) …
Are pro-regenerative therapies the future of osteoarthritis disease modification?
TL Vincent, PG Conaghan - Osteoarthritis and Cartilage, 2023 - oarsijournal.com
Osteoarthritis (OA) has historically been regarded as a disease of imbalance between
synthetic, anabolic responses in the joint tissues and catabolic, degradative ones. Since …
synthetic, anabolic responses in the joint tissues and catabolic, degradative ones. Since …
Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?
NE Lane, LS Simon, J Tambiah - Osteoarthritis and Cartilage …, 2025 - oarsiopenjournal.com
journal homepage: www. elsevier. com/journals/osteoarthritis-and-cartilage-open/2665-
9131 https://doi. org/10.1016/j. ocarto. 2024.100546 Received 11 November 2024; Accepted …
9131 https://doi. org/10.1016/j. ocarto. 2024.100546 Received 11 November 2024; Accepted …